VIEKIRA PAK associated drug-induced interstitial lung disease: Case series with systematic review of literature
Open Access
- 25 June 2019
- journal article
- letter
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 25 (2) , 218-222
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- EASL Recommendations on Treatment of Hepatitis C 2016Journal of Hepatology, 2017
- Serious Pulmonary Toxicity Secondary to Novel Hepatitis C Antiviral Therapy in a Liver Transplant RecipientMayo Clinic Proceedings, 2015
- Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virusHepatology, 2015
- Simeprevir with peginterferon and ribavirin induced interstitial pneumonitis: First case reportWorld Journal of Gastroenterology, 2015
- ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCVNew England Journal of Medicine, 2014
- ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with CirrhosisNew England Journal of Medicine, 2014
- Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with RibavirinNew England Journal of Medicine, 2014
- Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with RibavirinNew England Journal of Medicine, 2014
- Pegylated interferon induced interstitial pneumonitis in a patient with hepatitis C infectionRevista Española de Enfermedades Digestivas, 2010
- Pneumonitis as A Consequence of (Peg)Interferon-Ribavirin Combination Therapy for Hepatitis C: a Review of the LiteratureDigestive Diseases and Sciences, 2009